Background: Voriconazole is a potent antifungal drug with complex pharmacokinetics
caused by time-dependent inhibition and polymorphisms of metabolizing enzymes. It also …

Abstract Background and Objectives The effect of ontogeny in drug-metabolizing enzymes
on pediatric pharmacokinetics is poorly predicted. Voriconazole, a potent antifungal, is …

Voriconazole is a potent antifungal agent used for the treatment of invasive fungal infections
caused by Aspergillus and Candida species in adult and pediatric patients. Voriconazole …

Voriconazole is a potent triazole with broad-spectrum antifungal activity against clinically
significant and emerging pathogens. The present population pharmacokinetic analysis …

Background Voriconazole, a first-line antifungal drug, exhibits nonlinear pharmacokinetics
(PK), together with large interindividual variability but a narrow therapeutic range, and …

ABSTRACT Voriconazole (VRC), a first-line agent for the treatment of invasive fungal
infections, is mainly metabolized by human cytochrome P450 (CYP) 2C19. In this study, a …

Voriconazole is among the first-line antifungal drugs to treat invasive fungal infections in
children and known for its pronounced inter-and intraindividual pharmacokinetic variability …

The aim of this study was to evaluate factors that impact on voriconazole (VRC) population
pharmacokinetic (PPK) parameters and explore the optimal dosing regimen for different …

Numerous population pharmacokinetic studies on voriconazole have been conducted in
recent years. This review aimed to comprehensively summarize the population …

Objectives Voriconazole is a classical antifungal drug that is often used to treat CNS fungal
infections due to its permeability through the BBB. However, its clinical use remains …